MARKET

LUCD

LUCD

Lucid Diagnostics Inc.
NASDAQ
0.7965
-0.0025
-0.31%
After Hours: 0.7999 +0.0034 +0.43% 18:30 04/19 EDT
OPEN
0.7950
PREV CLOSE
0.7990
HIGH
0.8100
LOW
0.7650
VOLUME
118.26K
TURNOVER
0
52 WEEK HIGH
1.850
52 WEEK LOW
0.7637
MARKET CAP
38.43M
P/E (TTM)
-0.6315
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LUCD last week (0408-0412)?
Weekly Report · 6d ago
Lucid Diagnostics: Strong Buy Rating with Significant Market Potential Despite Near-Term Losses
TipRanks · 6d ago
U.S. RESEARCH ROUNDUP- Blackstone, Coupang, Wells Fargo
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Blackstone, Coupang, Wells Fargo & Co and Union Pacific raise their targets. 4D Molecular Therapeutics and Astera Labs are among the companies with new coverage on Monday.
Reuters · 6d ago
LUCID DIAGNOSTICS INC <LUCD.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $8 FROM $8.5
Reuters · 6d ago
Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham
Dow Jones · 04/12 08:47
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Benzinga · 04/12 08:37
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
TipRanks · 04/11 20:45
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
TipRanks · 04/10 17:50
More
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.

Webull offers Lucid Diagnostics Inc stock information, including NASDAQ: LUCD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUCD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LUCD stock methods without spending real money on the virtual paper trading platform.